Rectal Cancer Survival Rate
The rectal cancer survival rate is relatively high, with approximately 92 percent of patients who are diagnosed with stage 1 rectal cancer surviving five years or longer after their diagnosis. Additionally, thanks to the development of increasingly effective treatments, even patients who are diagnosed with late-stage cancer are surviving longer than they have in the past. Almost 90 percent of patients with stage 3A rectal cancer survive five years or longer – and this number doesn’t account for patients who have been diagnosed in recent years, when rectal cancer therapies have shown more promise than ever before.
The rectal cancer survival rate is trending upward, and Moffitt Cancer Center is committed to continuing this progress until a cure is available for all patients. That’s why our team of researchers and oncologists:
- Designs an individualized treatment plan for each patient, taking the time to account for the unique factors that can influence the patient’s outcome.
- Provides patients with opportunities to enroll in clinical trials, if so desired, so that they can be among the first to benefit from promising new rectal cancer treatment options.
- Actively develops better early detection tools, increasing the number of patients who are diagnosed in early stages and have correspondingly better prognoses.
Individuals who would like to learn more about the rectal cancer survival rate or the specific factors that could impact their own outcomes can come to Moffitt Cancer Center. Referrals are not required to make an appointment. To plan your visit, call 1-888-663-3488 or submit a new patient registration form online.